Clinical Outcome of Epidermal Growth Factor Receptor mutated (EGFR+) Non-small cell lung cancer (NSCLC) patients with first-line tyrosine kinase inhibitors (TKI) resistance on Osimertinib (CONTROL)
- Conditions
- metastatic EGFR mutated non small cell lung cancerAcquired resistance to first line EGFR inhibitor
- Registration Number
- ACTRN12617000993392
- Lead Sponsor
- Medical Oncology Department, Liverpool Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method